

Index

a

acetylcholine esterase 39, 325
 adenosine kinase 184
 adenylosuccinate synthetase 60
 adipocyte lipid-binding protein 169
 affinity 13, 20
 – definition 13 f.
 alanine scanning 69
 allosteric binding site 162 f., 300
 – caspase-3 300
 ancillary binding sites 162 f.
 antibody 40 ff.
 avidin 60
 avidity 12 f., 20, 22 f.
 – definition 13 f.
 – effective concentration 22 f.

b

Barrier, rigid body 55 ff., 61 f.
 BCR-Abl 222
 binding affinity, intrinsic 56 ff.
 binding modes, multiple 243
 binding site 67, 78, 83
 – location of 67
 – mapping 67 ff., 83
 – – computational methods 83
 – water 78
 binding to p38 α 207
 biochemical screening 231
 bisubstrate inhibitor 39

c

C5a receptor 303
 carbonic anhydrase 39, 275, 309, 327, 350, 353
 – pseudo-dynamic libraries 353
 caspase-1 299
 caspase-3 296 ff., 300
 – allosteric site 300
 CDK2 205

chelate effect 18, 21, 29, 150
 – cooperativity 29
 chemical graphs 92
 chemical space 92
 CHO interactions 205
 chymotrypsin 72
 classification 158
 click chemistry 313 ff., 328 f., 325 ff., 328 ff.
 – bioconjugation 328, 338 f.
 – – 1,3-dipolar cycloaddition 332
 – – DNA 332
 – – for proteomics 330
 – – tagging in living cells 328
 – in drug discovery 316 ff., 320
 – HIV protease inhibitors 321
 – – library generation 316
 – – natural products derivatives 317
 – – synthesis of neoglycoconjugates 320
 – *in situ* 325, 327
 – – acetylcholine esterase 325
 – – carbonic anhydrase 327
 – reactions 324 ff.
 – – 1,3-dipolar cycloaddition 315 ff., 326
 – – water-based 315, 326, 332
 clinical candidates 219
 – for approval 219
 – probability 219
 combinatorial chemistry, see also dynamic
 combinatorial chemistry 341
 combinatorial libraries 341
 – generation 341
 – – split and mix technology 341
 complexity, molecular 5
 cooperativity 24 ff.

d

dendrimers 36, 40
 dihydrodipicolinate reductase 171

- disulfide bond 286, 290, 324
 - conjugation energy 286
 - for glycoarrays 324
 - reducing agent 290
 - thermodynamics 286
- diversity, chemical 4f.
- dock 200
- docking 125 ff., 200, 242
 - for fragment optimization 242
 - for library design 200
- druggability 163
- drug-like properties 95 f.
- drugs 113 ff., 197
 - fragments present in 113
 - marketed injectable 115
 - marketed oral 115
- dynamic combinatorial chemistry 342 ff., 346 f., 350 ff., 356 f.
 - application to biological systems 347 ff., 350, 356
 - – acetylcholinesterase 352
 - – carbonic anhydrase 350
 - – concanavalin A 356
 - – lysozyme 352
 - – neuraminidase 351
 - – oligonucleotides 357
 - – wheat germ agglutinin 357
- dynamical combinatorial X-ray crystallography (DCX) 353
 - – CDK2 353
- methodologies 346
- dynamic combinatorial library 342 ff., 347, 354
 - building blocks 343 ff.
 - extended tethering 354
 - pseudo-dynamic libraries 347
 - reactions 343 ff.
 - receptor molding 343
 - self-screening process 342
 - substrate casting 343

e

- elastase 72 ff., 78 ff.
 - binding pockets 74
 - crystal structures of 72 f.
 - – dielectric constant 73
 - inhibitors 75
 - internal water 79
 - plasticity 75
 - surface waters 80
 - water molecule distribution 78
- enthalpy 19, 21 f.
- enthalpy/entropy compensation 21, 26, 32 f.

- entropic barrier to binding 55
- entropy 19, 21, 55 ff.
 - consequences of Linking Ligands 55
 - rotatable bond 58
- entropy, conformational 25
- entropy, rigid body 151
- Erm-AM 188
- ESI-MS 267 ff., 271, 275
 - affinity chromatography 271 ff.
 - as a screening technique 257 ff., 275
 - basic parameters 275 f.
 - buffer conditions 275
 - control experiments 271
 - detected interactions 271
 - ionization conditions 275
 - signal abundances 275

f

- factor VIIa 228 ff.
 - exosite 229 f.
 - fragment screen 229
- FK506 binding protein, FKBP 78, 184
- FKBP 163
- fragment 219 ff.
- fragment assembly, see fragment linking 167, 171
 - NMR-guided 167
 - NMR SOLVE 171
- fragment elaboration 181, 187 f., 190
 - energetic analysis 188
 - iterative library design 188, 190
 - potency gains 190
- fragment engineering, see fragment elaboration 240
- fragment library 89, 91, 96 ff., 99, 113, 152 ff., 156, 158, 160, 195 ff., 199, 201, 217 ff., 222
 - ADMET properties 153
 - bromine atoms 217, 219, 222
 - characterization 152
 - cheminformatics 91
 - cofactors 160
 - design 89 ff., 152
 - drug fragment library 197
 - filtering of 153
 - for X-ray crystallography 195, 217 f.
 - fragments of marketed drugs 113 ff.
 - intellectual property 92
 - kinase-library 199
 - lead-like 98
 - MCSS 125
 - phosphatase library 201
 - practical example 99
 - privileged fragment library 197

- purity 152
- quality control 201
- REOS 153
- rule-of-five 94
- SAR by NMR 156, 158
- SHAPES 154
- solubility 156
- synthetic handles 217
- targeted libraries 197
- WOMBAT 99

fragment library, linking 149

fragment linking 57, 59, 150, 168, 170, 173, 181 ff., 187, 240, 257 ff., 277, 293, 297

- combinatorial advantage 178
- energetic analysis 183
- expected potency 187
- experimental examples 59
- interligand NOE 170
- NMR ACE 173
- Potency Gains 181
- SAR by MS 277
- SAR by NMR 168, 180
- spin label 170
- Tethering 293, 297
- – with Extenders 297
- theoretic treatment 57, 150f.

fragment optimization 241, 243f.

- activity increase 244
- combinatorial libraries 243
- increase in activity 244
- linear libraries 241

fucosyltransferase 323

functional genomics 158 ff.

g

glycogen phosphorylase 61

GOLD 200

h

HCV protease 184

hemagglutination 28, 40

high-throughput screening 3, 64, 215, 341

- low-quality interactions 64

hit rate 5, 107, 219, 221

hot spots 69, 193, 293

human kinome 224

i

interleukin-2 293 ff.

- dynamic suffrage 294

- Tethering 295

- X-ray structures of 295

intrinsic binding affinity 56

Isothermal Titration Calorimetry (ITC) 26f.

j

Jencks, William 6, 149f.

Jnk3 169

k

kinome, human 224

l

lead-like properties 94, 215, 218

LFA 184

library 219 ff.

- diversity 220

ligand efficiency 6, 62f., 206

- intrinsic 63

ligand, bivalent 13

ligand, oligovalent 12f., 33

- scaffolds 33f.

ligand, polyvalent 15, 35, 37

- scaffolds 35f.

- synthesis 37f.

linear library 241

linker 25, 36f., 288, 291

- binding mode 291
- conformational entropy 25, 36
- influence on 291
- Tethering 288, 291
- – entropic costs 288

linking efficiency 243

lysozyme 78

m

Mass Spectrometry, see ESI-MS 250

Mass Spectrometry, see Tethering 285

MCSS, see multiple copy simultaneous search 168

MMP3 61

multi-copy simultaneous search 78, 125 ff., 132

- comparison with experiment 137f.
- comparison with GRID 135 ff.
- functional groups 128
- functionally maps 132 ff.
- interaction energies 127
- ligand design 138 ff.
- method 137
- multiple solvent crystal structure 137f.
- NMR 138
- protein flexibility 141
- topology file 127

Multiple Solvent Crystal Structure Method 67 ff.

multivalency 11 ff., 15 ff., 19, 24f., 26, 32, 39f.

- additivity 19

- antibodies 40
- cooperativity 24
- definitions 12
- design rules 32
- enhancement 15
- experiment studies 16
- experimental studies 26 ff.
- hetero-bivalent systems 39
- hetero-multivalency 11
- homo-multivalency 11
- lead discovery 39
- mechanism for dissociation 18
- thermodynamics 19 ff.
- MurF 261
- open conformation 261
- closed conformation 261

n

- NMR 159 ff., 167, 249 ff., 261
 - and X-ray crystallography 249 ff.
 - hit triaging by 251, 261
 - in the drug discovery process 250
 - SAR by NMR 149, 167
- NMR screening 208
 - ligand-based 208
 - – STD 208
 - – Water-LOGSY 208
- NMR-based screening 163 ff., 167, 169 f., 253
 - ligand-based 163 ff., 167
 - measurmat by NMR 164 f.
 - – K_d values 164
 - – linewidths 164
 - – STD 164
 - – transferred NOE 164
 - – WATERLOGSY 164
 - paramagnetic probes 169
 - protein-based 165, 253
 - TINS 169
 - PTP 1B 253
 - SLAPSTIC 170
 - spin labels 170
- non-classic hydrogen bonds 205
- Nuclear Magnetic Resonance, see NMR 7
- peptide deformylase 78
- probe molecules 67 ff., 71, 74
 - binding sites 71
 - clustering 74
- protein classification 158 ff.
- protein tyrosin phosphoton 18, PTP-18 184
- protein tyrosine phosphatase 1B 251 ff., 257 ff., 292 f.
 - core replacement 259
 - crystallography 251 ff.
 - from 259
 - HTS 252
 - inhibitors 257 ff.
 - monoacid replacements 258
 - NMR 251 ff.
 - open conformation 293
 - open form 293
 - polar surface area 258
 - potency and selectivity 257
 - Tethering 292
- PTP-1B, see protein tyrosine phosphatase 1B 253, 256
 - inhibitors 253
 - noncatalytic 256
 - open form 253
 - site 256
 - – NMR screening 256
 - states of oxidation 253
 - – NMR screening 256

r

- RECAP 113 f., 153
- recognition pocket 64
- ribonuclease A 71
- rigid body 55 ff.
- rigid body barrier 61
- rigid body barrier to binding 55
- rigid body entropy 55
- RNA 276 ff.
- rotatable bonds 58
 - entropic penalty 58
- rule of 3 96 ff., 153, 196, 219
 - commercially available compounds 153
- rule of 5 153, 196, 218

s

- oral drugs 113
 - structural fragments 113
- p**
- p38 MAP kinase 174, 207
- p38 α 174
- Pak4 235 ff.
- paramagnetic probes 169
- peptide deformylase 78
- probe molecules 67 ff., 71, 74
 - binding sites 71
 - clustering 74
- protein classification 158 ff.
- protein tyrosin phosphoton 18, PTP-18 184
- protein tyrosine phosphatase 1B 251 ff., 257 ff., 292 f.
 - core replacement 259
 - crystallography 251 ff.
 - from 259
 - HTS 252
 - inhibitors 257 ff.
 - monoacid replacements 258
 - NMR 251 ff.
 - open conformation 293
 - open form 293
 - polar surface area 258
 - potency and selectivity 257
 - Tethering 292
- PTP-1B, see protein tyrosine phosphatase 1B 253, 256
 - inhibitors 253
 - noncatalytic 256
 - open form 253
 - site 256
 - – NMR screening 256
 - states of oxidation 253
 - – NMR screening 256
- s**
- SAR 63
 - hypersensitive 63
- SAR by MS 277
- SAR by NMR 7, 149, 151, 156, 167, 181 ff.
- Scaffold for 33
- self-assembled monolayer 18
- SHAPES 154, 169

SMILES 93
 solvent mapping 68, 77
 solvent, organic 68
 solvent, organic probe molecule 73
 – binding sites 73
 stromelysin 60, 184f.
 structure-activity relationship 63
 structure-based drug design 4
 subtilisin 72
 Surface Plasmon Resonance Spectroscopy 27
 Syk 234f.
 – Pak4 as surrogate 235
 synchrotron 203, 217

t
 Tar RNA 276
 telavancin 39
 Tethering 285 ff., 289, 292 f., 297, 303, 305 ff., 354
 – advantages and disadvantages 289
 – general process 285 f.
 – GPCRs 303
 – protein tyrosine phosphatase 1B 292
 – protein-protein interactions 293
 – related approaches 306
 – thymidylate synthase 289 ff.
 – using functional screening 305
 – – disulfide formation 306
 – – imine formation 307
 – – metal-mediated 307
 – with extenders 289, 292, 297, 354
 – – dynamic combinatorial libraries 354
 – – for fragment linking 297
 thermolysin 78
 – crystal structures 78
 – solvent interaction sites 78
 thrombin 207

thymidylate synthase 289 ff.
 toxins, AB₅ 18, 29
 tryptase 60

v

vancomycin 17, 28, 60, 272
 – conformational entropy 28

w

water binding sites 78 ff., 81 f.
 – conservation of 81
 – general properties of 82
 WDI 95
 WOMBAT 96
 World Drug Index 93, 95

x

X-ray crystallography 194 f., 201 ff., 207, 215 ff., 222, 226, 233 f., 249 ff., 262
 – and NMR 207 ff., 249 ff.
 – as a screening technique 194 ff., 216 ff., 222, 226, 233 f.
 – – concentrations 226
 – – fragment optimization 234
 – – selection of hits 233
 – co-crystallization 262
 – Data Collection 202
 – Data Processing 203
 – flow chart 222 ff.
 – fragment screening 201 f., 217, 262
 – – co-crystallization 201
 – – soaking 201, 217
 – in the drug discovery process 250
 – NMR pre-screening 262
 – structural genomics 249
 – structure solution 204
 – tpdel
 – – flow-chart 204